ALLM (Calpain inhibitor II) is a potent inhibitor of calpain and cathepsin proteases. ALLM inhibits neuronal cell death and improves chronic neurological function after spinal cord injury (SCI)^[1][2]. In Vivo: ALLM (Calpain inhibitor II) (0.5 mg/kg) is injected every 24 h for 5 days after SCI and inhibits the activation of calpain but not that of caspase 3. ALLM prevents this neuronal cell death^[2].
ALLM (0.05-2.5 mg/kg; i.p.; every 24 h for 1 week) reduces motor disturbances after spinal cord injury (SCI)^[2].